Genomics and Personalized Medicine Act of 2010
Latest action · May 27, 2010 Referred to the House Committee on Energy and Commerce.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMay 27, 2010
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Genomics and Personalized Medicine Act of 2010 - Requires the Secretary of Health and Human Services (HHS) to establish the Office of Personalized Healthcare, the purpose of which shall be to coordinate HHS activities related to genomics and personalized medicine with those of other agencies and entities to ensure that personalized medicine meets the highest standards of safety, efficacy, and clinical validity and utility.
Sets forth provisions related to the collection of genetic and genomic data, including providing for a national biobank.
Requires the Secretary, acting through the Director of the Centers for Disease Control and Prevention (CDC), to establish the Committee on the Evaluation of Genomic Applications in Practice and Prevention.
Directs the Secretary to: (1) improve genomics and personalized medicine training; (2) establish a committee to examine barriers to personalized medicine product development; and (3) review billing, coverage, and reimbursement methodologies for personalized medicine products and services.
Requires the Secretary, acting through the Administrator of the Centers for Medicare & Medicaid Services (CMS) and the Commissioner of Food and Drugs (FDA), to: (1) establish a committee to carry out a comparative analysis of laboratory review requirements; (2) facilitate the use of personalized medicine products to assess the risk for and reduce incidence of adverse drug reactions; and (3) include personalized medicine products in adverse event reporting systems.
Authorizes the Secretary, acting through the Commissioner, to require the sponsor of a drug or biological product to: (1) develop a companion diagnostic test under certain circumstances; and (2) conduct additional postmarket studies of drugs shown to be more or less effective in certain racial and ethnic subpopulations.
Requires the Commissioner to collaborate with the Federal Trade Commission (FTC) to identify and terminate advertising campaigns that make false, misleading, deceptive, or unfair claims about the benefits or risks of personalized medicine products.
Requires the Director of CDC to: (1) expand efforts to increase awareness about genomics and personalized medicine; and (2) analyze marketing of personalized medicine products for which consumers have direct access.
Cosponsors 6
Members who signed on, in the order they did. Signatures ran from May 27, 2010 to Jul 30, 2010; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-CA | Anna G. Eshoo | Original | May 27, 2010 |
| D-NJ | Robert E. Andrews | Jul 13, 2010 | |
| D-CO | Jared Polis | Jul 14, 2010 | |
| D-PA | Tim Holden | Jul 15, 2010 | |
| D-FL | Alcee L. Hastings | Jul 21, 2010 | |
| D-MA | Michael E. Capuano | Jul 30, 2010 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred May 27, 2010 |
Actions 2
Everything that happened, newest first.
- May 27, 2010Introduced in House
- May 27, 2010Referred to the House Committee on Energy and Commerce.
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To secure the promise of personalized medicine for all Americans by expanding and accelerating genomics research and initiatives to improve the accuracy of disease diagnosis, increase the safety of drugs, and identify novel treatments, and for other purposes.
- Short Titles as Introduced
- Genomics and Personalized Medicine Act of 2010
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Advisory bodies
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Education programs funding
- Executive agency funding and structure
- Genetics
- Government studies and investigations
- Health
- Health care costs and insurance
- Health information and medical records
- Health programs administration and funding
- Health technology, devices, supplies
- Marketing and advertising
- Medical education
- Medical research
- Medical tests and diagnostic methods
- Medicare
- Organ and tissue donation and transplantation
- Research administration and funding
Text 1
Each version as it was printed, newest first.
- May 27, 2010Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.